Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
Public ClinicalTrials.gov record NCT00300963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Study identification
- NCT ID
- NCT00300963
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 275 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2004 (Type not available)
- Primary completion
- Oct 2005 (Actual)
- Completion
- Oct 2005 (Actual)
- Last update posted
- Feb 15, 2013
2004 – 2005
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Little Rock | Arkansas | 72201 | — |
| GSK Investigational Site | Anaheim | California | 92805 | — |
| GSK Investigational Site | Cerritos | California | 90703 | — |
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | Glendale | California | 91206 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | Pico Rivera | California | 90660 | — |
| GSK Investigational Site | Rosemead | California | 91770 | — |
| GSK Investigational Site | San Diego | California | 92123 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| GSK Investigational Site | North Miami | Florida | 33161 | — |
| GSK Investigational Site | Atlanta | Georgia | 30308 | — |
| GSK Investigational Site | St Louis | Missouri | 63118 | — |
| GSK Investigational Site | Clementon | New Jersey | 08021 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19131 | — |
| GSK Investigational Site | Austin | Texas | 78756 | — |
| GSK Investigational Site | Irving | Texas | 75062 | — |
| GSK Investigational Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00300963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00300963 live on ClinicalTrials.gov.